Immunocore (IMCR) Competitors $36.31 +0.10 (+0.28%) Closing price 04:00 PM EasternExtended Trading$36.29 -0.02 (-0.06%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. GRFS, TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, PCVX, and CYTKShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Grifols TG Therapeutics Nuvalent Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Does the media prefer GRFS or IMCR? In the previous week, Grifols had 4 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Grifols and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.85 beat Grifols' score of 0.58 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in GRFS or IMCR? 84.5% of Immunocore shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer GRFS or IMCR? Grifols presently has a consensus target price of $10.30, indicating a potential upside of 3.62%. Immunocore has a consensus target price of $58.89, indicating a potential upside of 62.18%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has better valuation & earnings, GRFS or IMCR? Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.88$169.80M$1.178.50Immunocore$310.20M5.88-$51.09M-$0.43-84.44 Is GRFS or IMCR more profitable? Grifols has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Immunocore -6.48%-5.86%-2.09% Which has more volatility & risk, GRFS or IMCR? Grifols has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. SummaryGrifols beats Immunocore on 9 of the 16 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / Sales5.88303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book5.047.678.125.65Net Income-$51.09M-$55.28M$3.25B$257.91M7 Day Performance3.68%2.50%0.97%2.09%1 Month Performance14.54%11.70%7.36%11.13%1 Year Performance-6.59%4.89%31.31%18.40% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.333 of 5 stars$36.31+0.3%$58.89+62.2%-7.2%$1.82B$310.20M0.00320GRFSGrifols3.8994 of 5 stars$9.72-0.2%$10.30+6.0%+24.7%$6.68B$7.81B8.3123,822News CoverageTGTXTG Therapeutics3.4049 of 5 stars$38.92+5.0%$43.80+12.5%+77.5%$6.18B$329M162.17290NUVLNuvalent3.1882 of 5 stars$84.59+4.5%$119.60+41.4%+6.4%$6.07BN/A-19.2740Insider TradeLNTHLantheus4.6282 of 5 stars$83.06+2.2%$131.20+58.0%-39.5%$5.75B$1.53B23.60700News CoveragePositive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.1928 of 5 stars$89.15+2.8%$91.00+2.1%+74.1%$5.67B$130.13M-31.73140Analyst ForecastAnalyst RevisionAXSMAxsome Therapeutics4.7309 of 5 stars$112.33+3.1%$172.33+53.4%+34.0%$5.53B$385.69M-19.47380Analyst RevisionTLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/AAnalyst RevisionCRSPCRISPR Therapeutics2.69 of 5 stars$56.42-0.7%$71.75+27.2%-8.9%$4.87B$37.31M-12.48460Insider TradeAnalyst RevisionGap UpPCVXVaxcyte1.8072 of 5 stars$36.38+1.3%$136.50+275.2%-54.1%$4.69BN/A-9.12160Positive NewsCYTKCytokinetics4.0425 of 5 stars$38.58+4.2%$70.92+83.8%-31.5%$4.61B$18.47M-7.29250Insider Trade Related Companies and Tools Related Companies GRFS Competitors TGTX Competitors NUVL Competitors LNTH Competitors RYTM Competitors AXSM Competitors TLX Competitors CRSP Competitors PCVX Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMCR Stock Alerts